AI Tokens
Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

IQVIA Holdings Inc., EBITDA calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Add: Net income attributable to noncontrolling interest — 5 29 36 25
Add: Income tax expense 260 163 72 116 59
Earnings before tax (EBT) 1,351 1,134 380 343 343
Add: Interest expense 416 375 416 447 414
Earnings before interest and tax (EBIT) 1,767 1,509 796 790 757
Add: Depreciation and amortization 1,130 1,264 1,287 1,202 1,141
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,897 2,773 2,083 1,992 1,898

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


A consistent upward trajectory is observed across all profitability metrics from 2018 to 2022, characterized by a significant acceleration in financial performance between the 2020 and 2021 fiscal years. While growth was incremental during the first three years of the period, the subsequent two years demonstrate a substantial expansion in both operating and net earnings.

EBITDA Growth Trends
Earnings before interest, tax, depreciation and amortization grew steadily from US$ 1,898 million in 2018 to US$ 2,083 million in 2020. A sharp inflection point occurred in 2021, with EBITDA rising to US$ 2,773 million, and further increasing to US$ 2,897 million by the end of 2022. This represents a cumulative increase of approximately 52.6% over the five-year window.
Operating Profitability (EBIT)
EBIT mirrored the EBITDA trend but experienced a more pronounced surge in the later years. Operating income remained relatively flat between 2018 and 2020, moving from US$ 757 million to US$ 796 million. However, EBIT nearly doubled in 2021 to US$ 1,509 million and continued its climb to US$ 1,767 million in 2022, indicating improved operational efficiency and scaling.
Net Income and EBT Performance
Earnings before tax (EBT) and net income exhibited greater volatility in the early period, with net income declining from US$ 259 million in 2018 to US$ 191 million in 2019. Following this dip, a rapid growth phase began in 2021, where net income surged to US$ 966 million, eventually reaching US$ 1,091 million in 2022. The growth rate of net income significantly outpaced the growth rate of EBITDA during the 2020-2022 interval.
Analysis of Depreciation and Amortization
A substantial and persistent gap is observed between EBITDA and EBIT, signifying high non-cash charges. In 2022, the difference between EBITDA (US$ 2,897 million) and EBIT (US$ 1,767 million) was US$ 1,130 million. The magnitude of this spread suggests a capital-intensive operational structure or the presence of significant intangible asset amortization.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Enterprise Value to EBITDA Ratio, Current

IQVIA Holdings Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 44,519
Earnings before interest, tax, depreciation and amortization (EBITDA) 2,897
Valuation Ratio
EV/EBITDA 15.37
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 32.43
Amgen Inc. 17.42
Bristol-Myers Squibb Co. 10.74
Danaher Corp. 24.92
Eli Lilly & Co. 46.09
Gilead Sciences Inc. 16.57
Johnson & Johnson 16.65
Merck & Co. Inc. 14.06
Pfizer Inc. 13.22
Regeneron Pharmaceuticals Inc. 15.04
Thermo Fisher Scientific Inc. 24.43
Vertex Pharmaceuticals Inc. 26.93
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.53
EV/EBITDA, Industry
Health Care 20.66

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

IQVIA Holdings Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 53,832 55,061 47,884 42,823 38,267
Earnings before interest, tax, depreciation and amortization (EBITDA)2 2,897 2,773 2,083 1,992 1,898
Valuation Ratio
EV/EBITDA3 18.58 19.86 22.99 21.50 20.16
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc. 13.31 13.44 — — —
Amgen Inc. 12.97 13.22 — — —
Bristol-Myers Squibb Co. 9.46 8.65 — — —
Danaher Corp. 18.42 21.05 — — —
Eli Lilly & Co. 37.76 29.86 — — —
Gilead Sciences Inc. 13.89 8.57 — — —
Johnson & Johnson 14.78 14.47 — — —
Merck & Co. Inc. 13.91 12.18 — — —
Pfizer Inc. 6.12 8.64 — — —
Regeneron Pharmaceuticals Inc. 15.27 6.68 — — —
Thermo Fisher Scientific Inc. 20.25 20.21 — — —
Vertex Pharmaceuticals Inc. 14.91 18.92 — — —
EV/EBITDA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 13.58 13.16 — — —
EV/EBITDA, Industry
Health Care 14.00 14.33 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 53,832 ÷ 2,897 = 18.58

4 Click competitor name to see calculations.


Between 2018 and 2022, a divergent trend is observed between the growth of Enterprise Value (EV) and Earnings Before Interest, Tax, Depreciation, and Amortization (EBITDA), which directly influenced the EV/EBITDA valuation multiple.

Enterprise Value Trend
Enterprise Value experienced a consistent upward trajectory from 2018 to 2021, rising from 38,267 million USD to a peak of 55,061 million USD. A slight contraction occurred in 2022, with the value decreasing to 53,832 million USD, though it remained significantly higher than the 2018 baseline.
EBITDA Growth
Operational profitability demonstrated steady and uninterrupted growth throughout the five-year period. EBITDA increased annually, moving from 1,898 million USD in 2018 to 2,897 million USD in 2022, reflecting a sustained improvement in earnings capacity.
EV/EBITDA Ratio Analysis
The valuation multiple exhibited a non-linear trend. The ratio climbed from 20.16 in 2018 to a peak of 22.99 in 2020, indicating that Enterprise Value grew at a faster rate than EBITDA during the initial three years. However, a reversal occurred in 2021 and 2022, with the ratio descending to 19.86 and 18.58, respectively. This downward trend in the latter two years suggests that EBITDA growth began to outpace the growth of Enterprise Value, leading to a relative compression in the valuation multiple.

The overall analysis indicates that while the absolute scale of both Enterprise Value and EBITDA increased over the period, the company ended the sequence with a lower valuation multiple than it started with in 2018, suggesting a more earnings-supported valuation by the end of 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?